Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-04-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerheartcardiacradiationventricular
  Phrases that lowered it: openlabelmgsubjectsaminotransferase
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 5.5% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Disease area, neurology: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Sponsor's past trials: 1939 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 323 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 9.1% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Keywords listed: 7 (lowers risk) · Design
• Blinding: none (raises risk) · Design
• Drug's FAERS reports marked serious: 93.9% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain NCT01266967 · started 2011 · scored riskier than 81% of active trials completed
• An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor NCT01619774 · started 2012 · scored riskier than 78% of active trials completed
• Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 NCT01072175 · started 2010 · scored riskier than 82% of active trials completed
• A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors NCT01340846 · started 2012 · scored riskier than 42% of active trials completed
• Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors NCT01340833 · started 2011 · scored riskier than 66% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.